Verdict card (component)
✓ Established | for Barth syndrome (accelerated approval); other indications remain Investigational
A mitochondria-targeting tetrapeptide that became the first FDA-approved mitochondrial-targeted therapeutic when it received accelerated approval as Forzinity in September 2025 for Barth syndrome — an ultra-rare X-linked cardioskeletal disease affecting ~150 patients in the US. Engineered to localize selectively to the inner mitochondrial membrane via cardiolipin binding, where it stabilizes electron transport chain function and reduces oxidative damage. The Barth syndrome approval was supported by the TAZPOWER trial; broader mitochondrial-disease applications (primary mitochondrial myopathy, dry AMD) continue in development with mixed-to-positive results.
Evidence signal row
- ✓ FDA accelerated approval September 2025 — Forzinity for Barth syndrome ≥30 kg
- ✓ First-in-class mitochondria-targeted therapeutic
- ! Other indications still Investigational — MMPOWER-3 missed primary endpoint in mitochondrial myopathy; dry AMD ongoing
Our verdict (3 sentences)
Elamipretide’s regulatory arc finally landed in 2025 with FDA accelerated approval for Barth syndrome — the first approved mitochondria-targeted therapeutic, and a rare-disease success after a long and complicated development history. We rate it Established for Barth syndrome (the approved indication, supported by TAZPOWER trial data); for the broader mitochondrial-disease applications it’s been investigated for — primary mitochondrial myopathy where Phase 3 missed, and dry AMD where Phase 3 is still running — the verdict remains Investigational. Continued accelerated-approval status is contingent on confirmatory trials, so the Barth syndrome verdict could move depending on the post-marketing data.
Mechanism
Elamipretide (originally known as MTP-131, SS-31, or Bendavia) is a synthetic 4-amino-acid peptide with the sequence D-Arg-2′,6′-dimethyl-Tyr-Lys-Phe-NH2. The non-natural amino acids and amide-capped C-terminus provide protease resistance and the specific charge profile needed for mitochondrial targeting.
The molecule’s selective mitochondrial localization is the key mechanistic feature. The alternating cationic and aromatic residues create an amphipathic structure that binds cardiolipin — a phospholipid uniquely concentrated in the inner mitochondrial membrane. After cellular uptake, elamipretide accumulates 1,000–5,000-fold in mitochondria versus cytoplasm.
At the inner membrane, elamipretide:
- Stabilizes cardiolipin-cytochrome c interactions
- Reduces cardiolipin peroxidation under oxidative stress
- Preserves cristae structure and electron transport chain efficiency
- Reduces mitochondrial reactive oxygen species generation
Net effect in mitochondrial dysfunction contexts: improved ATP production, reduced oxidative damage, preserved mitochondrial morphology.
The mechanism is well-characterized in cell culture and animal models — multiple independent groups have replicated the cardiolipin-binding biology.
What the evidence shows
Phase 2 MMPOWER-1, MMPOWER-2 (primary mitochondrial myopathy, 2017–2018): Open-label and short-duration RCT showed modest improvements in 6-minute walk distance, fatigue, and muscle function.
Phase 3 MMPOWER-3 (Karaa et al, Neurology 2023): 218 patients with primary mitochondrial myopathy, 24-week double-blind RCT. Did not meet primary endpoint (change in 6-minute walk distance) at the prespecified analysis. Some secondary endpoints showed trends but the primary failure was the regulatory-relevant result.
Barth syndrome (TAZPOWER trial): Trial in this rare X-linked cardiolipin-remodeling disorder. Knee extensor muscle strength improved from baseline during the open-label portion. After multiple FDA review cycles (initial Complete Response Letters requiring additional analyses, then NDA resubmission accepted), the FDA granted accelerated approval as Forzinity in September 2025 for Barth syndrome patients weighing ≥30 kg. Continued approval is contingent upon verification of clinical benefit in confirmatory trial(s) — standard accelerated-approval framework. EMA orphan designation was granted in May 2021; full EMA approval has not yet been granted as of this review.
Dry age-related macular degeneration (Phase 3 ReGAIN trial): Reading out late 2026; if positive, would represent a much larger commercial indication.
Heart failure with preserved ejection fraction (HFpEF): Phase 2 data not strong enough to advance.
Acute kidney injury after cardiac surgery (RECOMMEND trial): Did not meet primary endpoint.
The pattern: clear mechanism, occasional positive trials in narrow populations (Barth syndrome), broader application trials have generally missed their primary endpoints. The drug is doing something; whether what it’s doing translates to clinical benefit in the populations originally targeted has been less consistent than hoped.
Dosing literature
Trial protocols have used:
- 40 mg subcutaneous daily (standard dose in mitochondrial myopathy trials)
- Some Phase 2 ophthalmologic protocols use intravitreal administration for AMD
- Pediatric dosing weight-adjusted in Barth syndrome (which affects children)
There is no approved dose for general use in the US — only the EMA-approved Barth syndrome indication has formal dosing guidance.
Risks and adverse events
Reported in clinical trials:
- Injection site reactions (very common; subcutaneous injections produce significant local irritation, sometimes leading to discontinuation)
- Headache
- Mild GI symptoms (nausea, abdominal pain)
- Fatigue (which may be confounded by the underlying mitochondrial disease)
Less common:
- Hypertension elevations
- Mild hematologic effects
Long-term safety: Multi-year exposure data exists from MMPOWER extension cohorts. No major safety signals beyond the local injection site issues. The overall profile is favorable for a chronically-administered peptide.
The injection site reaction problem has been substantial enough that it impacts adherence in real-world use; alternative formulations (long-acting depot, oral formulations) are under development.
Regulatory status
| Region | Status | Notes |
|---|---|---|
| United States | Approved (Forzinity) | FDA accelerated approval September 19, 2025, for Barth syndrome in patients ≥30 kg. First FDA-approved mitochondria-targeted therapeutic. Continued approval contingent on confirmatory trials. |
| European Union | Orphan designation only | EU/3/21/2430 granted May 20, 2021. Full EMA approval not yet granted. |
| United Kingdom | Not approved | |
| Other markets | Not approved | Stealth running expanded access programs in some jurisdictions for patients <30 kg or in countries without approval. |
Manufacturer: Stealth BioTherapeutics. The company has had a complicated regulatory journey with this molecule; multiple Phase 3 trials, multiple FDA review cycles, and ongoing development across several indica
Quick Facts
| Also Known As | SS-31, MTP-131, Bendavia |
|---|---|
| Sequence | D-Arg-Dmt-Lys-Phe-NH2 (where Dmt = 2',6'-dimethyltyrosine) |
| Molecular Formula | C32H49N9O5 |
| Molecular Weight | 639.8 Da |
| PubChem CID | 11764719 |
Research Parameters
| Half-Life | ~ 2-4 hours (estimated from preclinical and clinical pharmacokinetic data) |
|---|---|
| Stability | Lyophilized powder is stable for at least 24 months when stored at -20°C, protected from light and moisture. After reconstitution in sterile saline or bacteriostatic water, the solution should be stored at 2-8°C and used within 24 hours, although some studies indicate stability for up to 7 days under refrigeration. |
| Solubility | Sterile Saline (0.9% Sodium Chloride) or Bacteriostatic Water (0.9% Benzyl Alcohol) |
| Storage (Lyophilized) | -20°C, protect from light and moisture |
| Storage (Reconstituted) | 2-8°C (refrigerated), protect from light, use within 24 hours |
| Typical Research Dose | 40,000 mcg (40 mg) per day (from clinical trial protocols; weight-based doses of 50-250 mcg/kg are also used) |
| Cycle Parameters | In clinical research, administration is typically a daily subcutaneous injection for the duration of the study period, which has ranged from 4 weeks to several months without a defined 'off' cycle. |
| Amino Acid Count | 7 |
Mechanism of Action
Elamipretide primarily functions by interacting with cardiolipin on the inner mitochondrial membrane, stabilizing its structure and preventing its peroxidation. This interaction helps maintain optimal mitochondrial membrane potential, cristae structure, and the efficiency of the electron transport chain.
Cardiolipin Stabilization: By binding to cardiolipin, elamipretide prevents the conversion of cytochrome c from an electron carrier to a peroxidase, thereby inhibiting the initiation of apoptosis and reducing reactive oxygen species (ROS) production at their source.
Electron Transport Chain Support: The stabilization of cardiolipin supports the proper assembly and function of respiratory chain supercomplexes (particularly complexes III and IV), enhancing oxidative phosphorylation and ATP production.
Reduction of Mitochondrial ROS: By improving electron flow and preventing electron leak, elamipretide significantly reduces the generation of superoxide and other damaging ROS, mitigating oxidative damage to mitochondrial and cellular components.
Inhibition of Mitochondrial Permeability Transition Pore (mPTP): The peptide helps maintain mitochondrial membrane integrity, making the mPTP less likely to open, which prevents the release of pro-apoptotic factors and subsequent cell death.
Research Applications
Cardiovascular Research: Studies in models of ischemia-reperfusion injury, heart failure, and myocardial infarction have shown that elamipretide can reduce infarct size, improve left ventricular function, and preserve mitochondrial structure. It is believed to protect cardiomyocytes from energy depletion and apoptotic death.
Neurological Research: In models of neurodegenerative diseases (e.g., Alzheimer's, Parkinson's) and acute neurological injury (e.g., stroke, traumatic brain injury), research indicates elamipretide may protect neurons by preserving mitochondrial function, reducing oxidative stress, and improving synaptic viability.
Rare Disease Research (Barth Syndrome): As the first drug to receive FDA Breakthrough Therapy designation for Barth syndrome, elamipretide has shown promise in clinical trials for improving cardiac output and exercise tolerance in patients with this genetic disorder linked to abnormal cardiolipin metabolism.
Ophthalmology Research: In models of dry age-related macular degeneration (AMD) and other retinal diseases, elamipretide has demonstrated potential to protect retinal pigment epithelial cells from mitochondrial dysfunction and oxidative damage, potentially slowing disease progression.
Aging and Frailty Research: Preclinical studies suggest the peptide may improve mitochondrial function in aged tissues, potentially addressing age-related declines in muscle function, exercise capacity, and overall cellular resilience.
Safety & Side Effects
Data from clinical trials indicate elamipretide is generally well-tolerated. The most commonly reported side effects in human trials have been mild injection site reactions (e.g., erythema, pain). No serious drug-related adverse events have been consistently reported in completed trials. Theoretical concerns are minimal due to its targeted mechanism and peptide nature, but long-term safety data beyond several months is still being collected. Anecdotal reports from the research community are scarce, as it is not a widely available research chemical.
Dosage Information
This information is derived from published research protocols only and is not intended for clinical use.
In human clinical trials, elamipretide has been administered via subcutaneous injection or intravenous infusion. Typical research doses in clinical studies have ranged from 0.05 mg/kg to 0.25 mg/kg. For example, in heart failure studies, a common dose was 40 mg per day via subcutaneous injection. Administration frequency is typically once daily. Study durations have varied from single-dose pharmacokinetic studies to trials lasting several weeks or months.
References
Birk, A. V., et al. 'The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin.' Journal of the American Society of Nephrology, 2013.
Szeto, H. H., and Birk, A. V. 'Serendipity and the discovery of novel compounds that restore mitochondrial plasticity.' Clinical Pharmacology & Therapeutics, 2014.
Chatfield, K. C., et al. 'Dysregulation of cardiolipin biosynthesis in pediatric heart failure.' Journal of Molecular and Cellular Cardiology, 2014.
Dai, W., et al. 'Bendavia, a mitochondria-targeting peptide, improves postinfarction cardiac function, prevents adverse left ventricular remodeling, and restores mitochondria-related gene expression in rats.' Journal of Cardiovascular Pharmacology, 2014.
Siegel, M. P., et al. 'Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice.' Aging Cell, 2013.
Zhao, K., et al. 'Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury.' Journal of Biological Chemistry, 2004.
Karaa, A., et al. 'Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy.' Neurology, 2018.